Phase 3
N=591
Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder
Post Traumatic Stress Disorder
Bottom Line
View on ClinicalTrials.gov: NCT04174170 ↗Enrolled (actual)
591
Serious AEs
0.9%
Results posted
May 2025
Primary outcome: Primary: Change From Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Score — -16.53; -18.28; -17.57 score on a scale — p=0.5165
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Brexpiprazole (Drug); Sertraline (Drug); Placebo (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Primary completion
- Jul 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Score |
-16.53; -18.28; -17.57 | 0.5165 |
| SECONDARY Change in Clinical Global Impression - Severity (CGI-S) Score |
-1.26; -1.31; -1.29 | 0.8215 |
| SECONDARY Change in Brief Inventory of Psychosocial Functions (B-IPF) Score |
-27.12; -31.79; -22.96 | 0.2331 |
Summary
This will be a 12-week, multicenter, randomized, double-blind trial evaluating the efficacy, safety, and tolerability of fixed-dose brexpiprazole + sertraline combination treatment in adult subjects with post-traumatic stress disorder.
Eligibility Criteria
Inclusion Criteria
- Male and female outpatients 18 to 65 years of age, inclusive, at the time of informed consent.
- Participants who have post-traumatic stress disorder (PTSD), diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), and confirmed by the Mini International Neuropsychiatric Interview (MINI).
- Onset of symptoms meeting the DSM-5 criteria for PTSD symptoms for a minimum of 6 months prior to screening.
Exclusion Criteria
- The index traumatic event that led to the development of PTSD took place > 9 years before screening.
- The index traumatic event occurred before age 16.
- Participants who have experienced a traumatic event within 3 months of screening.
- Participants who are receiving disability payments because of PTSD or any other psychiatric disorder; unless the disability payments will not be impacted by potential improvements demonstrated in the trial.
Data sourced from ClinicalTrials.gov (NCT04174170). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.